	US 12,303,614 B2
	Compositions and methods for improving mechanical properties of a tissue or for regenerating an injured or diseased tissue
Catherine K. Kuo, College Park, MD (US)
Assigned to University of Rochester, Rochester, NY (US)
Filed by University of Rochester, Rochester, NY (US)
Filed on May 3, 2023, as Appl. No. 18/311,592.
Application 18/311,592 is a division of application No. 16/800,151, filed on Feb. 25, 2020, granted, now 11,679,178.
Claims priority of provisional application 62/810,021, filed on Feb. 25, 2019.
Prior Publication US 2024/0009350 A1, Jan. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 27/24 (2006.01); A61B 5/00 (2006.01); A61L 27/38 (2006.01); A61L 27/54 (2006.01)

CPC A61L 27/24 (2013.01) [A61B 5/0048 (2013.01); A61L 27/3834 (2013.01); A61L 27/54 (2013.01); A61L 2300/254 (2013.01); A61L 2300/414 (2013.01); A61L 2430/06 (2013.01); A61L 2430/10 (2013.01); A61L 2430/20 (2013.01)]

18 Claims

1. A pharmaceutical composition comprising

(i) lysyl oxidase (LOX) or LOX like (LOXL) protein (LOX/LOXL) enhancer selected from the group consisting of a LOX polypeptide, a LOXL protein, a pre-proLOX polypeptide, a proLOX polypeptide, a nucleic acid encoding one or more of the polypeptides, an engineered cell expressing or having said nucleic acid, and a viral particle having the nucleic acid,

(ii) an agent selected from the group consisting of BMP-1, Fibronectin, Tolloid, Vitamin B6, Ascorbic acid, and Procollagen c proteinase, and

(iii) a pharmaceutically acceptable carrier or excipient.